Moderna, Inc. (MRNA)

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

No competitor list for this company yet.

• 5d agoPOSITIVE
  Moderna, Merck Cancer Vax Gives Hope

  Moderna Inc. and Merck & Co. have achieved a significant milestone in cancer treatment with their mRNA-based cancer vaccine. A late-stage trial demonstrated that the vaccine successfully prevented the recurrence of melanoma, offering substantial hope for patients and a new chapter for mRNA technology. This breakthrough, detailed in Bloomberg Opinion, highlights the potential of vaccines in training the immune system to combat cancer. For investors, this development could signal a strong future for Moderna's oncology pipeline and validate the long-term potential of mRNA applications beyond infectious diseases, potentially driving significant stock appreciation.

• 6d agoNEUTRAL
  Moderna’s personalized mRNA shot could reshape the fight against skin cancer — but it may also be overhyped

  Moderna's personalized mRNA cancer vaccine for melanoma has generated significant excitement among medical professionals and patients, signaling a potential paradigm shift in skin cancer treatment. However, market analysts caution that the current enthusiasm may be overblown, suggesting a need for tempered expectations. While the technology holds promise, its ultimate efficacy and market penetration remain subjects of debate. Investors should monitor clinical trial results and regulatory approvals closely, as the long-term impact on Moderna's stock price is contingent on overcoming these hurdles and demonstrating clear clinical and commercial advantages over existing therapies.

• 6d agoPOSITIVE
  Moderna, Merck Shares Soar on Cancer Vaccine Trial Success

  Moderna Inc. and Merck & Company Inc. shares experienced significant surges following the announcement of a successful Phase 3 clinical trial for their experimental personalized mRNA cancer vaccine, intismeran, in combination with Merck's Keytruda. The trial demonstrated a significant extension in recurrence-free survival for high-risk melanoma patients post-surgery. Moderna's stock jumped as much as 177% to $174.93, adding approximately $30 billion in market capitalization, while Merck's shares climbed 12% to an all-time high of $153.13. This breakthrough, marking the first statistically significant improvement over checkpoint inhibitors with an individualized treatment, could pave the way for market entry as early as next year, pending regulatory discussions. Further trials are underway for other cancer types.

• 6d agoNEGATIVE
  Azioni Moderna -20% dopo rally record, emergono dubbi sulla valutazione

  Moderna Inc. shares experienced a sharp 20% decline, closing at $138 after reaching a record high. This pullback occurred as investors took profits following positive Phase 3 trial results for a cancer vaccine. Despite analysts raising price targets, some valuations remained below Wednesday's close, indicating concerns that the stock may have already priced in much of the clinical progress. The significant retracement suggests that the market is reassessing Moderna's valuation in light of its recent rapid ascent.

• 7d agoPOSITIVE
  Moderna Surges as Stocks Rise & Long-Term Yields Retreat | Closing Bell

  Moderna Inc. experienced a significant surge in its stock price during the U.S. market close, coinciding with a broader market rally and a retreat in long-term yields. While the article does not provide specific figures for Moderna's performance, its inclusion in the 'Closing Bell' segment suggests notable investor activity. The retreat in long-term yields typically benefits growth stocks like those in the biotechnology sector, potentially indicating a favorable macroeconomic environment for Moderna. Investors may interpret this as a positive sign for the company's future prospects, especially given its pipeline and ongoing developments.